QTTB · XBRL financial data

Q32 Bio financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (QTTB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	(6,651)	0	53,737
Revenue from contracts with customers	2,702	33,971	3,208	1,156	—	—
Research and development	100,392	93,085	98,351	62,002	48,143	19,156
General and administrative	32,573	36,835	38,138	31,256	17,959	17,679
Total operating expenses	132,965	129,920	136,489	102,585	66,102	36,835
Other operating income (expense)	—	—	—	—	1,500	400
Operating income (loss)	(130,263)	(95,949)	(133,281)	(101,429)	(66,102)	16,902
Interest expense	—	—	—	1,500	—	—
Other income (expense)	1,569	185	134,479	14,349	4,125	1,182
Income tax expense (benefit)	0	0	715	0	21	0
Net income (loss)	(128,694)	(95,764)	(5,005)	(112,961)	(47,733)	29,821
Earnings per share, basic USD per share	—	(1.73)	(0.09)	(1.95)	(5.12)	2.42
Earnings per share, diluted USD per share	—	(1.73)	(0.09)	(1.95)	(6.58)	2.42
Weighted average shares, basic thousands of shares	—	55,283	57,400	57,835	9,321	12,301
Weighted average shares, diluted thousands of shares	—	55,283	57,400	57,835	9,658	12,315

Fiscal years (QTTB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	217,431	108,382	33,986	39,266	77,965	48,297
Short-term investments	—	—	141,040	0	0	—
Marketable securities	0	47,491	141,040	43,387	—	—
Prepaid and other current assets	2,133	7,129	5,989	1,001	3,912	6,753
Total current assets	219,564	191,909	181,015	83,914	81,877	55,050
Property and equipment, net	37,002	2,252	1,078	0	1,370	979
Right-of-use asset	5,897	15,607	20,563	650	5,722	5,100
Total assets	263,737	211,721	228,470	84,564	92,332	61,776
Accounts payable	4,722	2,366	1,144	3,234	2,989	879
Accrued liabilities	—	—	—	9,763	7,479	4,232
Total current liabilities	22,658	17,226	22,576	11,573	16,465	11,346
Lease liability, non-current	12,941	23,688	27,916	0	5,636	4,943
Total liabilities	67,742	42,070	50,492	11,573	86,657	19,762
Accumulated deficit	(328,368)	(424,132)	(429,137)	(542,098)	(234,814)	(204,993)
Total stockholders' equity	195,995	169,651	177,978	72,991	5,675	42,014
Total liabilities and equity	263,737	211,721	228,470	84,564	92,332	61,776
Common shares outstanding (cover page) thousands of shares	50,488	57,385	57,678	58,134	12,198	14,629

Fiscal years (QTTB's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(128,694)	(95,764)	(5,005)	(112,961)	(47,733)	29,821
Stock-based compensation	13,248	17,245	13,054	7,324	4,386	5,255
Net cash from operating activities	(94,332)	(109,751)	(113,661)	(96,230)	(67,715)	(33,543)
Purchases of property and equipment	3,733	2,396	1,285	228	75	0
Net cash from investing activities	204,896	(50,788)	36,716	101,326	19,925	7,000
Proceeds from issuing common stock	—	49,744	0	0	42,000	0
Net cash from financing activities	53,093	52,169	596	184	95,138	(3,125)
Net change in cash	163,657	(108,370)	(76,349)	5,280	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Q32 Bio	289,587	not reported	(4,418)*	29.9M	62.5 quarters	Q3 FY26 10-QSep 30, 2026
Kiora Pharmaceuticals	7,077	not reported	(1,892)*	4.4M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Brainstorm Cell Therapeutics	22	not reported	(895)	11.0M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Scienture Holdings	8,188	344	(3,132)*	41.1M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
LeonaBio	32,323	not reported	(16,958)*	9.4M	3.0 quarters	Q2 FY26 10-QJun 30, 2026
Mannatech	6,034	26,650	(792)*	1.9M	7.6 quarters	Q2 FY26 10-QJun 30, 2026
Traws Pharma	5,016	not reported	(7,504)*	15.4M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
BioCardia	4,117	not reported	(1,735)*	15.1M	2.4 quarters	Q2 FY26 10-QJun 30, 2026
Phio Pharmaceuticals	12,996	not reported	(4,035)*	11.6M	3.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.